×
The real winners from Trump’s ‘AI action plan’? Tech companies

The real winners from Trump’s ‘AI action plan’? Tech companies

Donald Trump’s AI summit in Washington this week was a fanfare-filled event catered to the tech elite. The president took the stage on Wednesday evening, as the song God Bless the USA piped over the loudspeakers, and then he decreed: “America must once again be a country where innovators are rewarded with a green light, not strangled with red tape, so they can’t move, so they can’t breathe.”

The message was clear – the tech regulatory environment that was once the focus of federal lawmakers is no longer.

“I’ve been watching for many years,” Trump continued. “I’ve watched regulation. I’ve been a victim of regulation.”

As Trump spoke to the crowd, he addressed them as “the group of smart ones … the brain power”. In front of him were tech leaders, venture capitalists and billionaires, including Nvidia’s CEO Jensen Huang and Palantir’s chief technology officer Shyam Sankar. The Hill and Valley Forum, an influential tech industry interest group, co-hosted the confab, along with the Silicon Valley All-in Podcast, which is hosted by White House AI and crypto czar David Sacks.

Dubbed “Winning the AI Race”, the forum was an opportunity for the president to deliver what he called the “AI action plan”, which aims to loosen restrictions on the development and deployment of artificial intelligence.

The cornerstone of that plan are three executive orders that Trump said will turn the US into an “AI export powerhouse” and roll back some of the rules put in place by the Biden administration, which included guardrails around safe and secure AI development.

“Winning the AI race will demand a new spirit of patriotism and national loyalty in Silicon Valley – and long beyond Silicon Valley,” Trump said.

One executive order targets what the White House calls “woke” AI and requires any company receiving federal funding to maintain AI models free from “ideological dogmas such as DEI”. But the other two focus on deregulation, a major demand of American tech leaders who have taken an increasingly bullish stand on government oversight.

One of those promotes the export of “American AI” to other countries and the other eases environmental rules and expedites federal permitting for power-hungry data centers.

Millions in lobbying

To get to this moment, tech companies have been forging a friendly relationship with Trump. The CEOs of Alphabet, Meta, Amazon and Apple donated to the president’s inauguration fund and met with him at his Mar-a-Lago estate in Florida. Sam Altman, the CEO of OpenAI, which makes ChatGPT, has become a close ally of Trump, and Nvidia’s Huang has also cozied up with the president with promises of investing $500bn in AI infrastructure in the US over the next four years.

“The reality is that big tech companies are still spending tens of millions of dollars to curry favor with lawmakers and shape tech legislation,” said Alix Fraser, the vice-president of advocacy for the nonprofit Issue One.

In a report released on Tuesday, Issue One looked at lobbying spending in 2025 and found that the tech industry has spent record-breaking sums. Eight of the largest tech companies spent a combined $36m – that’s an average of about $320,000 per day when Congress is in session, according to Issue One.

Meta spent the most, $13.8m, and has hired 86 lobbyists this year, according to the report. And Nvidia and OpenAI saw the biggest increases, with Nvidia spending 388% more than the same time last year, and OpenAI spending 44% more.

In the lead-up to Trump’s unveiling of his AI plan, more than 100 prominent labor, environmental, civil rights and academic groups countered the president and signed a “People’s AI action plan”. In a statement, the groups stressed the need for “relief from the tech monopolies” that they say “sacrifice the interests of everyday people for their own profits”.

“We can’t let big tech and big oil lobbyists write the rules for AI and our economy at the expense of our freedom and equality, workers and families’ wellbeing, even the air we breathe and the water we drink – all of which are affected by the unrestrained and unaccountable rollout of AI,” the groups wrote.

Meanwhile, tech companies and industry groups celebrated the executive orders. Microsoft, IBM, Dell, Meta, Palantir, Nvidia, Anthropic, xAI and others praised the plan. James Czerniawski, the head of emerging technology policy at the Consumer Choice Center, a pro-business lobbying group, heralded Trump’s AI plan as a “bold vision”.

“This is a world of difference from the hostile regulatory approach of the Biden administration,” Czerniawski concluded.

Source link
#real #winners #Trumps #action #plan #Tech #companies

ASUS Chromebook CM32 Detachable Leads the Lineup
ASUS Expands Chromebook Lineup in India With New CM14, CM15, and CM32 Models
	
Chromebooks aren’t exactly the most exciting laptops on the market, but they continue to be a popular option for students and anyone who primarily works in the cloud. Looking to capitalize on that demand, ASUS has launched three new Chromebooks in India, including a detachable 2-in-1 model that doubles as a tablet.



The new lineup consists of the ASUS Chromebook CM32 Detachable, Chromebook CM14, and Chromebook CM15. All three devices run ChromeOS and come with Google’s latest AI-powered features, along with cloud-first productivity tools aimed at students, educators, and young professionals. ASUS is also bundling three months of Google AI Pro with the devices, giving buyers access to Google’s AI tools and 5TB of cloud storage.



ASUS Chromebook CM32 Detachable Leads the Lineup







Leading the lineup is the ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.



ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.



Chromebook CM14 and CM15 Focus on Battery Life







If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.



One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.



Price and Availability



The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.





#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus

Leading the lineup is the ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.

ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.

Chromebook CM14 and CM15 Focus on Battery Life

If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.

One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.

Price and Availability

The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.

#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus">ASUS Expands Chromebook Lineup in India With New CM14, CM15, and CM32 Models
	
Chromebooks aren’t exactly the most exciting laptops on the market, but they continue to be a popular option for students and anyone who primarily works in the cloud. Looking to capitalize on that demand, ASUS has launched three new Chromebooks in India, including a detachable 2-in-1 model that doubles as a tablet.



The new lineup consists of the ASUS Chromebook CM32 Detachable, Chromebook CM14, and Chromebook CM15. All three devices run ChromeOS and come with Google’s latest AI-powered features, along with cloud-first productivity tools aimed at students, educators, and young professionals. ASUS is also bundling three months of Google AI Pro with the devices, giving buyers access to Google’s AI tools and 5TB of cloud storage.



ASUS Chromebook CM32 Detachable Leads the Lineup







Leading the lineup is the ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.



ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.



Chromebook CM14 and CM15 Focus on Battery Life







If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.



One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.



Price and Availability



The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.





#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus

ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.

ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.

Chromebook CM14 and CM15 Focus on Battery Life

If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.

One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.

Price and Availability

The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.

#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus">ASUS Expands Chromebook Lineup in India With New CM14, CM15, and CM32 Models

Chromebooks aren’t exactly the most exciting laptops on the market, but they continue to be a popular option for students and anyone who primarily works in the cloud. Looking to capitalize on that demand, ASUS has launched three new Chromebooks in India, including a detachable 2-in-1 model that doubles as a tablet.

The new lineup consists of the ASUS Chromebook CM32 Detachable, Chromebook CM14, and Chromebook CM15. All three devices run ChromeOS and come with Google’s latest AI-powered features, along with cloud-first productivity tools aimed at students, educators, and young professionals. ASUS is also bundling three months of Google AI Pro with the devices, giving buyers access to Google’s AI tools and 5TB of cloud storage.

ASUS Chromebook CM32 Detachable Leads the Lineup

ASUS Expands Chromebook Lineup in India With New CM14, CM15, and CM32 Models
	
Chromebooks aren’t exactly the most exciting laptops on the market, but they continue to be a popular option for students and anyone who primarily works in the cloud. Looking to capitalize on that demand, ASUS has launched three new Chromebooks in India, including a detachable 2-in-1 model that doubles as a tablet.



The new lineup consists of the ASUS Chromebook CM32 Detachable, Chromebook CM14, and Chromebook CM15. All three devices run ChromeOS and come with Google’s latest AI-powered features, along with cloud-first productivity tools aimed at students, educators, and young professionals. ASUS is also bundling three months of Google AI Pro with the devices, giving buyers access to Google’s AI tools and 5TB of cloud storage.



ASUS Chromebook CM32 Detachable Leads the Lineup







Leading the lineup is the ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.



ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.



Chromebook CM14 and CM15 Focus on Battery Life







If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.



One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.



Price and Availability



The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.





#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus

Leading the lineup is the ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.

ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.

Chromebook CM14 and CM15 Focus on Battery Life

If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.

One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.

Price and Availability

The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.

#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus

published late last week in the journal Nature Microbiology.

Good guy prions?

Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.

Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.

According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.

The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations).

Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections.

The researchers have coined these antibacterial fragments collected from prions as “prionins.”

The future of prionins

More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body.

At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing.

“For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”

With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.

#Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions">Deadly Proteins Behind Mad Cow Disease Might Help Us Fight Superbugs
                The next frontier of antibiotics might come from an unexpected place. Recent research identifies potential antibiotic candidates from inside prions—proteins capable of causing some of the deadliest brain infections ever known, such as mad cow disease.

 Scientists at the University of Pennsylvania used artificial intelligence to rapidly search hundreds of prions and prion-like proteins for peptides with antibacterial activity. They found several dozen promising candidates, two of which have already shown results treating bacterial infections in mice. The team’s findings establish “prion-related proteins as a productive source space for antibiotic discovery,” the scientists wrote in their paper, published late last week in the journal Nature Microbiology.

 Good guy prions? Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.

 Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.   According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.

 The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations). Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections. The researchers have coined these antibacterial fragments collected from prions as “prionins.”

 The future of prionins More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body. At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing. “For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”

 With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.      #Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions

published late last week in the journal Nature Microbiology.

Good guy prions?

Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.

Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.

According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.

The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations).

Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections.

The researchers have coined these antibacterial fragments collected from prions as “prionins.”

The future of prionins

More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body.

At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing.

“For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”

With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.

#Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions">Deadly Proteins Behind Mad Cow Disease Might Help Us Fight SuperbugsDeadly Proteins Behind Mad Cow Disease Might Help Us Fight Superbugs
                The next frontier of antibiotics might come from an unexpected place. Recent research identifies potential antibiotic candidates from inside prions—proteins capable of causing some of the deadliest brain infections ever known, such as mad cow disease.

 Scientists at the University of Pennsylvania used artificial intelligence to rapidly search hundreds of prions and prion-like proteins for peptides with antibacterial activity. They found several dozen promising candidates, two of which have already shown results treating bacterial infections in mice. The team’s findings establish “prion-related proteins as a productive source space for antibiotic discovery,” the scientists wrote in their paper, published late last week in the journal Nature Microbiology.

 Good guy prions? Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.

 Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.   According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.

 The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations). Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections. The researchers have coined these antibacterial fragments collected from prions as “prionins.”

 The future of prionins More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body. At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing. “For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”

 With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.      #Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions

The next frontier of antibiotics might come from an unexpected place. Recent research identifies potential antibiotic candidates from inside prions—proteins capable of causing some of the deadliest brain infections ever known, such as mad cow disease.

Scientists at the University of Pennsylvania used artificial intelligence to rapidly search hundreds of prions and prion-like proteins for peptides with antibacterial activity. They found several dozen promising candidates, two of which have already shown results treating bacterial infections in mice.

The team’s findings establish “prion-related proteins as a productive source space for antibiotic discovery,” the scientists wrote in their paper, published late last week in the journal Nature Microbiology.

Good guy prions?

Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.

Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.

According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.

The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations).

Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections.

The researchers have coined these antibacterial fragments collected from prions as “prionins.”

The future of prionins

More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body.

At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing.

“For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”

With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.

#Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions

Post Comment